Sunovion announces acceptance by FDA of NDA for Dasotraline to treat Binge Eating Disorder
This article was originally published here
Dasotraline’s pharmacokinetic profile, characterized by an extended half-life, supports its potential for sustained control of moderate-to-severe BED symptoms. The action date by the FDA under the Prescription Drug
The post Sunovion announces acceptance by FDA of NDA for Dasotraline to treat Binge Eating Disorder appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!